DURBYXLI Trademark

Trademark Overview


On Thursday, April 18, 2019, a trademark application was filed for DURBYXLI with the United States Patent and Trademark Office. The USPTO has given the DURBYXLI trademark a serial number of 88391480. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Wednesday, January 5, 2022. This trademark is owned by Eli Lilly and Company. The DURBYXLI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in...
durbyxli

General Information


Serial Number88391480
Word MarkDURBYXLI
Filing DateThursday, April 18, 2019
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateWednesday, January 5, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 18, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain
Translation of Words in MarkThe wording "DURBYXLI" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateWednesday, January 5, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Wednesday, January 5, 2022ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Wednesday, January 5, 2022ABANDONMENT - AFTER PUBLICATION
Tuesday, January 4, 2022TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, July 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 16, 2021EXTENSION 4 GRANTED
Friday, July 16, 2021EXTENSION 4 FILED
Friday, July 16, 2021TEAS EXTENSION RECEIVED
Tuesday, January 26, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 22, 2021EXTENSION 3 GRANTED
Friday, January 22, 2021EXTENSION 3 FILED
Friday, January 22, 2021TEAS EXTENSION RECEIVED
Tuesday, August 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, August 8, 2020EXTENSION 2 GRANTED
Friday, July 17, 2020EXTENSION 2 FILED
Saturday, August 8, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, July 17, 2020TEAS EXTENSION RECEIVED
Friday, January 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 15, 2020EXTENSION 1 GRANTED
Wednesday, January 15, 2020EXTENSION 1 FILED
Wednesday, January 15, 2020TEAS EXTENSION RECEIVED
Tuesday, August 13, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 18, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 18, 2019PUBLISHED FOR OPPOSITION
Wednesday, May 29, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 14, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, May 6, 2019ASSIGNED TO EXAMINER
Saturday, May 4, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, April 22, 2019NEW APPLICATION ENTERED IN TRAM